Programmed Cell Death News and Research

RSS

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

Calcitriol - active form of vitamin D - may protect us from radiation

Radiological health expert Daniel Hayes, Ph.D., of the New York City Department of Health and Mental Hygiene suggests that a form of vitamin D could be one of our body's main protections against damage from low levels of radiation.

8 Nov 2008

Genes that control cell death may play role in age-related hearing loss

Several genes that play a role in how our body's cells normally auto-destruct may play a role in age-related hearing loss, according to research published online in the journal Apoptosis - a journal devoted to the topic of cell suicide, or programmed cell death.

19 Oct 2008

On the trail of a targeted therapy for blood cancer

Investigators from the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine are focusing on a family of blood proteins that they hope holds a key to decreasing the toxic effects of chemotherapy in children and adults.

12 Oct 2008

Multifunctional polymer nanoparticles pass critical in vivo test

In an effort to overcome the drug resistance that often occurs in cancer, a team of investigators has developed a nanoparticle made of a blend of polymers that first releases a powerful anticancer drug and then delivers an agent that tricks a drug-resistant cell into committing suicide. Now, tests in mice with human breast cancer have shown that these blended nanoparticles are effective in maintaining high levels of both drugs in the vicinity of tumors.

28 Sep 2008

Unsuccessful drug against anxiety opens a novel gateway for the treatment of cancer

According a new study, unsatisfying drug for anxiety reveals scientists a promising novel anti-cancer drug target.

4 Sep 2008

Early trigger for type-1 diabetes found in mice

Scientists at the Stanford University School of Medicine are shedding light on how type-1 diabetes begins.

26 Aug 2008

By amplifying cell death signals, scientists make precancerous cells self-destruct

When a cell begins to multiply in a dangerously abnormal way, a series of death signals trigger it to self-destruct before it turns cancerous. Now, in research to appear in the August 15 issue of Genes & Development, Rockefeller University scientists have figured out a way in mice to amplify the signals that tell these precancerous cells to die. The trick: Inactivating a protein that normally helps cells to avoid self-destruction.

17 Aug 2008

Finding cancer's original cell key to treatments

Cancer biologists are turning their attention to the normal cells that give rise to cancers, to learn more about how tumor growth might be stopped at the earliest opportunity.

11 Aug 2008

Cannabinoid cell surface receptor plays a tumor-suppressing role in human colorectal cancer

CB1 is well-established for relieving pain and nausea, elevating mood and stimulating appetite by serving as a docking station for the cannabinoid group of signaling molecules. It now may serve as a new path for cancer prevention or treatment.

3 Aug 2008

Methadone shows promise against leukemia

Researchers in Germany have discovered that methadone, an agent used to break addiction to opioid drugs, has surprising killing power against leukemia cells, including treatment resistant forms of the cancer.

3 Aug 2008

Quick formula could forecast which cancers chemo could kill

Researchers at the University of Rochester Medical Center have coined a simple formula that predicts how well a certain chemotherapy will work for targeting brain and other nervous system cancers. The formula, which publishes mid-July in Cancer Chemotherapy and Pharmacology, is pegged to two important proteins that compose such hard-to-kill tumors - one of which, ironically, makes them so drug-resistant in the first place.

15 Jul 2008

Discovery of gene mechanism could lead to new therapeutic strategies to fight metastatic disease

Virginia Commonwealth University and VCU Massey Cancer Center researchers have uncovered how a gene, melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), induces a bystander effect that kills cancer cells not directly receiving mda-7/IL-24 without harming healthy ones, a discovery that could lead to new therapeutic strategies to fight metastatic disease.

1 Jul 2008

Cancer cells revert to normal at specific signal threshold

Cancer starts when key cellular signals run amok, driving uncontrolled cell growth. But scientists at the Stanford University School of Medicine report that lowering levels of one cancer signal under a specific threshold reverses this process in mice, returning tumor cells to their normal, healthy state. The finding could help target cancer chemotherapy to tumors while minimizing side effects for the body's healthy cells.

1 Jul 2008

Nerve cells derived from stem cells may one day provide improved brain treatments

Scientists at the Burnham Institute for Medical Research have, for the first time, genetically programmed embryonic stem (ES) cells to become nerve cells when transplanted into the brain, according to a study published in The Journal of Neuroscience.

24 Jun 2008

Nerve cells derived from embryonic stem cells and transplanted into mice may lead to improved brain therapies

24 Jun 2008

Nanoparticles trigger built-in cell-death signal to overcome drug resistance

One of the most vexing problems in treating cancer is the propensity of tumors to develop resistance to a wide range of anticancer drugs. Over 70 percent of ovarian cancer patients, for example, have drug-resistant tumors at the time of their initial diagnosis, and virtually all patients who relapse have drug-resistant tumors.

15 Jun 2008